Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
The fact that multiple Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, when multiple insiders sell stock over a specific duration, shareholders should take notice as that could possibly be a red flag.
過去一年中，多名再生元製藥股份有限公司 (NASDAQ:REGN) 內部人士出售了大量股票，這可能引起投資者的關注。分析內部交易時，了解內部人員是否購買股票通常比了解他們是否出售更有價值，因爲出售可能會傳遞模糊信息。然而，當多個內部人員在一定時間內出售股票時，股東應該注意到，這可能是一個紅旗。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
儘管我們永遠不會建議投資者僅基於公司董事的行動做出決策，但邏輯推斷您應該關注內部人士是否買賣股票。
Regeneron Pharmaceuticals Insider Transactions Over The Last Year
過去一年中再生元製藥公司的內部交易
Over the last year, we can see that the biggest insider sale was by the Executive VP and GM of Industrial Operations & Product Supply, Daniel Van Plew, for US$9.8m worth of shares, at about US$952 per share. That means that an insider was selling shares at slightly below the current price (US$1,100). As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 24% of Daniel Van Plew's holding.
過去一年，我們可以看到最大的內部人員銷售來自產業運營和產品供應的執行副總裁兼總經理丹尼爾·範普魯，總價值980萬美元的股份，每股約952美元。這意味着內部人員在略低於當前價格（1100美元）的價格上出售了股份。一般來說，當內部人員以低於當前價格出售股票時，我們認爲這是令人沮喪的，因爲這表明他們對低估值感到滿意。雖然內部人員的賣出並不是一個積極的信號，但我們不能確定它是否意味着內部人員認爲這些股票已經完全價值，因此這只是一個微弱的信號。值得注意的是，這次銷售僅佔丹尼爾·範普魯持有的24%。
Insiders in Regeneron Pharmaceuticals didn't buy any shares in the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
在過去一年中，再生元製藥的內部人士沒有購買任何股票。下圖顯示了過去一年中公司和個人的內部交易。單擊下面的圖表，您可以查看每個內部交易的詳細信息！
I will like Regeneron Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.
如果我看到內部人員進行大規模股票買入，我會更喜歡再生元製藥。在等待的同時，請查看這份免費的低估和小盤股票列表，其中有相當數量的最近內部買入。
Insider Ownership Of Regeneron Pharmaceuticals
再生元製藥的內部所有權
For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It's great to see that Regeneron Pharmaceuticals insiders own 4.0% of the company, worth about US$4.8b. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
對於普通股東來說，了解公司內部人員持有多少股份很有價值，因爲高內部所有權通常使公司領導層更加關注股東利益。再生元製藥內部人員擁有公司的4.0%股份，價值約48億美元，這是一個好的跡象，股東會感到高興，因爲這表明管理層的利益與其他股東的利益是一致的。
So What Do The Regeneron Pharmaceuticals Insider Transactions Indicate?
那麼，再生元製藥的內部交易意味着什麼？
It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Regeneron Pharmaceuticals insider transactions don't fill us with confidence. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
實際上，上個季度內沒有內部人員交易再生元製藥股票並不意味着什麼。內部人員擁有大量股票是令人鼓舞的，但是我們希望看到更多的內部買入，因爲過去一年的再生元製藥內部交易並沒有讓我們充滿信心。如果您和我一樣，您可能會想到這家公司會增長還是縮小。幸運的是，您可以查看這份爲其未來提供分析師預測的免費報告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果您想查看另一家公司的信息-一家潛在具有優秀財務狀況的公司-請不要錯過這個帶有高股權回報率和低債務的有趣公司免費列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋？對內容有任何疑慮？請直接與我們聯繫。或者，發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。